Skip to main content
Premium Trial:

Request an Annual Quote

Perlegen Announces Two More Pharma Collaborations

NEW YORK, Dec. 20-Perlegen, the Affymetrix spin-off, announced two pharmaceutical company deals in pharmacogenomics and disease-related SNP research.


The company said today that it has struck a deal with Pfizer to study the genetics of cardiovascular disease, using its chip-based genotyping technique to identify disease-associated genetic variations.


Further details of the collaboration, including financial information, were not disclosed.


On Dec. 18, Perlegen said it would collaborate with Eli Lilly to identify disease markers using its SNP portfolio and its chip-based whole genome screening technology. In this deal, Perlegen will get research funding, milestone payments,  royalties, and an equity investment from Lilly. Perlegen also retains some rights to develop products based on the research.


It has been a busy week for Perlegen: Yesterday, the company said it had struck a similar dealwith Bristol-Myers Squibb.

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.